Professor Lorna Harries gained her PhD from University College London in 1994, and now holds a personal chair in molecular genetics at the University of Exeter Medical School. Lorna established the RNA-mediated disease mechanisms group at Exeter in 2006, and now also holds a position as co-founder, co-director and Chief Scientific Officer at SENISCA Ltd, a spin out company founded on the Harries lab’s research. Lorna has interests in omics approaches to the study of human ageing and age-related disease processes in humans, and her work takes a genes to systems approach, ranging from ‘big data’ analyses to detailed individual molecular analysis of particular genes. Her team were the first to report dysregulation of alternative splicing as a new, and druggable, hallmark of ageing, and a demonstration of this in human primary cells.
Remko van Leeuwen has more than 25 years of research experience under his belt, both in the industry as well as in the academic arena.
He has a medical background, and been trained as a clinical epidemiologist, and has extensive experienced in clinical infectious disease management. He has obtained a Ph.D. in clinical HIV studies.
After completing his Ph.D., he decided on a career switch and terminated his hospital-based clinical activities. Over the last 2 decades, he has various positions in drug development and clinical trial conduct. He has designed and executed numerous clinical trials and pre-clinical development programs.
He has been the team leader of large multi-national successful research projects. He carries in-depth knowledge of product development, including regulatory requirements, medical affairs, biostatistics, and data analysis. He has followed the NIABA Masterclass of Biobusiness 2009/2010. In 2011 he founded Madam Therapeutics.
To cure or to significantly improve today's diabetes therapeutics by maturing our small molecule leads into an orally active drug to treat diabetes, do so by regenerate insulin-producing beta cells in the pancreatic islet. 2. To create, identify, and implement the best approaches to create and/or support growing biotechnology and pharmaceutical companies with innovative tools and processes.
Head of Pharmaceutical Research
Skilled in analytical chemistry, formulation development, chemistry, and team management.
Focusing on science and people development.
S Dravida is the Founder CEO of Transcell Biologics Pvt. Ltd www.transcellbio.science, innovating new vistas in healthcare/biotechnology industry and markets from India. She is an entrepreneurial technocrat of global standing having worked in the USA, Canada and India in the domains of stem cell research/biobanking and product development. She has unique blend of skills of wet lab, product development to managing business.
Under her stewardship, Transcell Biologics, a knowledge driven technology investing entity has evolved from its inception as an R&D unit to a fully integrated biotechnology enterprise encompassing a well balanced business portfolio offering indigenous technologies on biobanking, in vitro products for drug discovery research, intellectual property in regenerative medicine/Immunotherapy for clinical practice.
She is a biologist by education with clinical informatics research experience having associated professionally with the University of North Carolina, USA, Ottawa Health Research Institute, Canada. S Dravida has peer reviewed publications and patents to her credit. She holds IP in the field of large scale cell productions & novel druggable formulations. Outside of work, she explores Monasteries, night skies and reads Science fiction.
A quote that she relates to: It's the possibility of having a dream come true that makes life interesting and when your dream is with real intent and true, the whole universe will conspire and make you realize the dream
Thomas T. Tibbitts, Ph. D. founded DTI in May 2020 to integrate the latest technologies in genomics, biology and computing to bring new medicines to patients suffering with respiratory infections and diseases of the lung. Dr. Tibbitts, serving as its CEO and Head of Research and Development, has over twenty years experience in the pharmaceutical industry. Most recently, Dr. Tibbitts served as Senior Vice President for Computational Research at Goldfinch Bio, where he launched the Kidney Genome Atlas and built a world-class team for sequencing thousands of patients and integrating transcriptomics and epigenetics for the discovery of novel genetic targets in kidney disease. He was part of the initial team that launched Goldfinch with $55M series A funding in 2016 at Third Rock Ventures. At Infinity Pharmaceuticals, Thomas contributed to multiple drug programs for over a decade which lead to Copiktra (duvelisib), a medication approved to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and IPI-549, currently in clinical development for the treatment of advanced urothelial cancer. Dr. Tibbitts holds a PhD in Biophysics from Brandeis University and has numerous patents and peer-reviewed publications in drug discovery, oncology, enzymology and structural biology.
Afreen Allam: Founder/CEO Ms. Allam is a graduate of North Carolina State University with a double major in microbiology and biochemistry. She subsequently graduated from Duke University’s Fuqua School of Business with her Masters of Business Administration in finance and banking. She has over 10 years of research in nanomedicine and her extensive studies on applications of carbon nanotechnology in drug delivery and bio-imaging led to the patenting of the Carbon NanoDot technology in 2013. At the age of 17 Ms.Allam had her first DNA sequence published and filed a patent at the age of 20. She has presented at numerous biomedical conferences including the Drugs & Diagnostics Conference, Biotech Research Symposium, and National Tech Connect Conference. She was a Forbes 30 under 30 finalist, Bustle Upstart awardee, Triangle Business Journal’s Rising Star Women in Business for 2019, Durham’s Women’s Achievement awardee, finalist for Mass Challenge, and NYU’s Endless Frontier Lab accelerator finalist.
Head of Orphan Diseases Division
Venn Therapeutics is a highly innovative drug discovery incubator and immuno-oncology company developing a pipeline of novel, first-in-class agents that precisely target key mechanisms of cancer, fibrosis, and NASH, focused on integrin-mediated activation of TGF-β.Venn’s broad portfolio includes a pipeline of first-in-class antibodies targeting integrins for the treatment of cancer and fibrotic disorders. Venn leverages pioneering translational research working with world class scientific researchers at the cutting edge of the emerging field of immuno-oncology.
Learn from the industry’s top leading professionals. Increase your knowledge and partners under one roof
Benefits, limitations, and diversity of AI model in drug and target discovery.
Deep generative autopilot for the real world design of novel lead compound.
Complexity simplified; comprehensive data management for complex world.
Drug Targets with Genomic Support: A Genomics-based Strategic Framework for Improving Target Discovery and Accelerating Drug Development
The Sponsorship opportunity at Meridian Drug Discovery come with countless benefits.
Meetings, meet with industry's most renowned decision-makers exclusively. Dine and discuss business in a private setting; competitor friendly atmosphere.1
The exhibition, deliver yourself from the irrelevant audience, surround yourself with the right decision-makers in a business-driven environment; choose quality over quantity.3
Presentation, Devote yourself to science, feed the next generation with experience-based knowledge. Grasp the opportunity to apprise yourself and your organization.2
Networking, a new partner, the next funding, is just one introduction away. introduce yourself to the right people in the right place. Initiate a new business relationship by being in the right place at the right time.4